46 CHEMICALS KNOWLEDGE HUB Issue 1 / July 2025 The global GLP-1 analogues market is projected to reach USD 471.10 billion by 2032 from USD 47.49 billion in 2024, at a CAGR of 33.2% during the forecast period. The growth of this market is majorly driven by the presence of a robust R&D pipeline, improved efficacy offered by GLP-1 drugs, and the high demand from end users. On the other hand, high entry barriers to new entrants due to the current duopoly restrain the growth of this market. The GLP-1 analogues market is segmented by product into Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Xultophy, Soliqua, Zepbound, Bydureon, and other products. Ozempic accounted for the largest market owing to its high adoption and established brand recognition. Zepbound held the fastest growth rate of 50.3% during the forecast period due to rapid growth in adoption, growing focus on anti-obesity medicines (AOMS), and anticipated regulatory approvals across different geographies. Based on the format, the GLP-1 analogues market is segmented into single-dose, multi-dose, and tablet formats. The single-dose format held the largest share (84.1%) of the GLP-1 analogues market in 2023. This segment is projected to reach USD 413.34 billion by 2032 from USD 40.10 billion in 2024, at a CAGR of 33.9% during the forecast period. The major factors driving the growth of this segment are the ease of administration, the growing availability of single dose autoinjectors, and the lower injection frequency. Based on the route of administration, the GLP-1 analogues market is segmented into subcutaneous and oral administration. Subcutaneous administration is further segmented based on injector type into pen and autoinjectors. The subcutaneous route held the largest share (92.7%) of the GLP-1 analogues market in 2023. This segment is projected to reach USD 453.72 billion by 2032 from USD 44.21 billion in 2024, at a CAGR of 33.8% during the forecast period. The major factors driving the growth of this segment are the presence of many marketed products administered subcutaneously, bypassing gastrointestinal tract-associated adverse effects, and faster onset of therapeutic action, among others. Based on the indication, the GLP-1 analogues market is segmented into diabetes, obesity, and other indications. Diabetes held the largest share of the GLP-1 analogues market in 2023. This segment is projected to reach USD 338.84 billion by 2032 from USD 37.93 billion in 2024, at a CAGR of 31.5% during the forecast period. The major factors driving the growth of this segment are the high demand for GLP-1 drugs for type 2 diabetes, the strong pipeline, and the advantages of GLP-1 analogues over other antidiabetic drugs. Based on end users, the global GLP-1 analogues market is segmented into home care settings, longterm care facilities, and hospitals & specialty clinics. The home care settings segment held the largest share (60.0%) of the GLP-1 analogues market in 2023. This segment is projected to reach USD 290.60 INNOVATION & TRENDS
RkJQdWJsaXNoZXIy MjY2OTA4MA==